Tracking legislation, court rulings, and regulatory frameworks shaping Cannabis access and prohibition worldwide.
NSW has taken a significant step by recognising that Cannabis presence is not impairment. But instead of adopting an impairment‑based model, the Government has created a narrow exemption that depends on registration, prescription proof, and administrative compliance. This report examines how the new framework reshapes driving laws while keeping zero‑tolerance largely intact.
A low‑harm plant became the target of high‑harm policies through stigma, curated evidence, and institutional self‑preservation. This report explains how the paradox formed, how it survived, and why it still shapes legal outcomes today.
Australia regulates hemp seed as a food at the point of sale but treats the crop as a drug risk in the field. This report explains the current laws, the compliance pressures facing growers, and why aligning agricultural and food‑safety frameworks is essential for a modern hemp industry.
Australia’s Cannabis debate is shaped by outdated treaties, federal scheduling, and confusing terminology. This report defines the true destination—full legalisation through descheduling—and maps the structural roadblocks that stand between Australia and that final stop.
The Glass-Steagall Act was created to stop financial giants from controlling every part of the banking system. Today, healthcare is facing the same problem. Insurers, pharmacies, PBMs, and data companies are merging into vertically integrated corporations that can set the price, approve the service, process the claim, and pay themselves. Cannabis policy shows how quickly a health market can be reshaped when corporate incentives dominate.
Sativex was the first modern Sheepshield — a corporate tincture disguised as innovation. Now that tinctures are legal and the acidic‑cannabinoid patent has expired, the wolf behind the wool is finally visible.
The U.S. hemp crackdown isn't just American news—it's a treaty-powered warning to the world. By realigning with the 1961 UN Single Convention, the U.S. is demonstrating how international law can be used to erase a multi-billion dollar industry overnight. This move threatens the foundation of global cannabis reform. For Australia, the path forward is clear: we must build a smarter, sovereign regulatory model or risk having our progress dictated by outdated global prohibition.
Cannabis decriminalisation reduces harm to individuals, but it does not change the system that supplies the product. When possession becomes safer, but supply remains illegal, the illicit market continues to thrive. Legalisation, by contrast, replaces criminal distribution with a regulated market that improves safety, reduces enforcement costs, and redirects public funds.
From corporate lobbying to entrenched investments, prohibition has created a system where profit comes before people. This post examines the financial forces that sustain prohibition and why the status quo remains so lucrative.
Australians can legally use medical Cannabis. Yet roadside drug testing laws, written in 2004, have not kept pace. Patients prescribed cannabis for pain or PTSD face licence suspension, fines, and job loss — even when they are not impaired.
